IMMUNOINFLAMMATORY MARKERS AND THEIR DYNAMICS UNDER IMMUNOCORRECTIVE THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE ASSOCIATED WITH ARTERIAL HYPERTENSION
Keywords:
Ischemic heart disease, arterial hypertension, immunocorrective therapy, hs-CRP, interleukin-6, interferon-γ, systemic inflammationAbstract
Ischemic heart disease associated with arterial hypertension is characterized by a high risk of cardiovascular complications and progression of atherosclerotic vascular damage. In recent years, systemic inflammation and immune dysregulation have been recognized as key pathogenetic mechanisms contributing to endothelial dysfunction and adverse cardiovascular remodeling. However, the effectiveness of immunocorrective therapy in modulating inflammatory and cytokine responses in this patient population remains insufficiently studied.
References
Libby P. Inflammation in atherosclerosis: from pathophysiology to practice // Journal of the American College of Cardiology. – 2021.
Ridker P.M. Anti-inflammatory therapy and cardiovascular risk reduction: insights into the IL-6 pathway // New England Journal of Medicine. – 2020.
Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease // New England Journal of Medicine. – 2021.
Abbas A.K., Lichtman A.H., Pillai S. Cellular and Molecular Immunology. – 9th ed. – Elsevier, 2018.
